Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SLXN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSilexion reports positive early data for SIL204 pancreatic cancer immunotherapy
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
high
Company announced positive preliminary immunotherapy findings for SIL204, its drug candidate targeting KRAS-driven pancreatic cancer, marking a clinical development milestone for the program.
Item 7.01 Press Release verify on EDGAR → -
medium
The 8-K filing provides only the press release title without detailed clinical data, efficacy metrics, or patient outcomes from the study.
Exhibit 99.1 view on EDGAR →
Summary
Silexion Therapeutics disclosed positive preliminary results for SIL204, its immunotherapy candidate for KRAS-driven pancreatic cancer. KRAS mutations are present in roughly 90% of pancreatic cancers and have historically been difficult to target, making any progress in this area potentially significant for patients with limited treatment options. Retail investors should note that the 8-K contains minimal detail—only the press release headline is provided, with no data on response rates, patient numbers, safety profile, or trial design.
The term 'preliminary' suggests early-stage findings that require validation in larger studies. Watch for the full press release or subsequent disclosures detailing the actual clinical data, including objective response rates, duration of response, and next steps for the SIL204 program. Without hard numbers, it's premature to assess whether these findings will translate into regulatory progress or commercial value.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Silexion Therapeutics filed an 8-K attaching a press release dated May 14, 2026; no material business event disclosed in the body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1
Press Release dated May 14, 2026
The 8-K attaches a press release dated May 14, 2026 as Exhibit 99.1. The body of the 8-K does not describe the content of the press release, so the nature and materiality of any disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify